New drug MAR002 takes first step toward treating acromegaly

NCT ID NCT07195175

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MAR002

What this could lead to

If safe, this could lead to a new treatment option for acromegaly, a condition caused by too much growth hormone.

What could go wrong

This is a very early Phase 1 trial in healthy men, not patients. It only tests safety and dosing, not whether it works for acromegaly. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Marea Site

    RECRUITING

    Tempe, Arizona, 85283, United States